ETF Series Solutions Trust Range Cancer Therapeutics ETF
CNCR
CNCR was delisted on the 27th of May, 2025.
28 hedge funds and large institutions have $12.8M invested in ETF Series Solutions Trust Range Cancer Therapeutics ETF in 2018 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 10 increasing their positions, 3 reducing their positions, and 3 closing their positions.
233% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 3
167% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 3
22% more funds holding
Funds holding: 23 → 28 (+5)
1.03% more ownership
Funds ownership: 21.13% → 22.16% (+1%)
5% less capital invested
Capital invested by funds: $13.5M → $12.8M (-$657K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$2.53M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$857K |
| 3 |
WCA
Waratah Capital Advisors
Toronto,
Ontario, Canada
|
+$371K |
| 4 |
PCM
Prelude Capital Management
New York
|
+$325K |
| 5 |
CIA
Choate Investment Advisors
Boston,
Massachusetts
|
+$277K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPL Financial
San Diego,
California
|
-$2.01M |
| 2 |
Jane Street
New York
|
-$761K |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$416K |
| 4 |
HighTower Advisors
Chicago,
Illinois
|
-$207K |
| 5 |
RPG
Risk Paradigm Group
Austin,
Texas
|
-$77K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
CIBC Private Wealth Group
Atlanta,
Georgia
| $12K | – | – | – |
|
|
AG
27
Advisor Group
Phoenix,
Arizona
| $12K | +$8.36K | +310 | +155% |
|
28
Fifth Third Bancorp
Cincinnati,
Ohio
| $10K | – | – | – |
|
|
29
HighTower Advisors
Chicago,
Illinois
| – | -$207K | -7,140 | Closed |
|
|
RPG
30
Risk Paradigm Group
Austin,
Texas
| – | -$77K | -2,650 | Closed |
|
|
IWM
31
IHT Wealth Management
Chicago,
Illinois
| – | -$21K | -750 | Closed |
|
CNCR Hedge Fund Activity: Q2 2018 in Review
28 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) for Q2 2018, worth a combined $12.8M — down 4.9% from $13.5M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new CNCR positions and 3 closed out — a net gain of 5 holders — while 10 added to existing stakes and 3 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $2.53M. The largest seller was LPL Financial, cutting an estimated $2.01M.
- 28 institutional investors held ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) as of Q2 2018, up from 23 in Q1 2018.
- Funds reported $12.8M of ETF Series Solutions Trust Range Cancer Therapeutics ETF stock for Q2 2018, down 4.9% quarter-over-quarter.
- 8 funds opened new ETF Series Solutions Trust Range Cancer Therapeutics ETF positions in Q2 2018 and 3 closed out, a net change of +5 holders.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF buyer in Q2 2018 was Morgan Stanley, an estimated $2.53M added.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF seller in Q2 2018 was LPL Financial, an estimated $2.01M sold.
Based on aggregated 13F filings for Q2 2018.